 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Review, Journal: Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs. (Pubmed Central) - Mar 11, 2024
Among the potential therapies, ibodutant, ibudilast, blautix, BOS-589, solabegron, vibegron, olorinab, ebastine, and ORP-101 have demonstrated possible effects but remain confirmed...Therefore, we should focus on developing new, efficient, and affordable medications for IBS-D. The government, insurers, and society must recognize this need and collaborate to ensure its fulfillment.
- |||| ORP-101 / OrphoMed
Trial completion, Trial completion date: A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - Mar 4, 2022
P2, N=321, Completed, Sponsor: OrphoMed, Inc.
The government, insurers, and society must recognize this need and collaborate to ensure its fulfillment. Active, not recruiting --> Completed | Trial completion date: Oct 2022 --> Oct 2021
- || ORP-101 / OrphoMed
Trial completion date: A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - Jan 11, 2022
P2, N=321, Active, not recruiting, Sponsor: OrphoMed, Inc.
Active, not recruiting --> Completed | Trial completion date: Oct 2022 --> Oct 2021 Trial completion date: Dec 2021 --> Oct 2022
- ||| ORP-101 / OrphoMed
Enrollment closed: A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - Jul 14, 2021
P2, N=320, Active, not recruiting, Sponsor: OrphoMed, Inc.
Trial completion date: Dec 2021 --> Oct 2022 Recruiting --> Active, not recruiting
- || ORP-101 / OrphoMed
Trial completion date, Trial primary completion date: A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - May 7, 2020
P2, N=320, Recruiting, Sponsor: OrphoMed, Inc.
Recruiting --> Active, not recruiting Trial completion date: Apr 2021 --> Oct 2021 | Trial primary completion date: Apr 2021 --> Oct 2021
- ORP-101 / OrphoMed
PHASE 1 RESULTS OF ORP-101, A NOVEL PARTIAL μ AGONIST, FULL Κ ANTAGONIST WITHOUT OPIOID-LIKE ADVERSE EFFECTS, WHICH IS BEING DEVELOPED TO TREAT IBS-D () - May 4, 2020 - Abstract #DDW2020DDW_4567;
Trial completion date: Apr 2021 --> Oct 2021 | Trial primary completion date: Apr 2021 --> Oct 2021 Results of the animal and healthy human subject studies to date are consistent with the hypothesis that ORP-101 acts peripherally on intestinal opioid receptors to treat IBS-D without the risk of CNS effects.
- ||| ORP-101 / OrphoMed
OrphoMed Pauses Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D https://t.co/US0Bm1DpLy (Twitter) - Mar 31, 2020
- |||| ORP-101 / OrphoMed
Enrollment open: A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - Dec 8, 2019
P2, N=320, Recruiting, Sponsor: OrphoMed, Inc.
Results of the animal and healthy human subject studies to date are consistent with the hypothesis that ORP-101 acts peripherally on intestinal opioid receptors to treat IBS-D without the risk of CNS effects. Not yet recruiting --> Recruiting
- | ORP-101 / OrphoMed
New P2 trial: A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D) (clinicaltrials.gov) - Oct 16, 2019
P2, N=320, Not yet recruiting, Sponsor: OrphoMed, Inc.